Vericel Corporation $VCEL Position Increased by Congress Asset Management Co.

Congress Asset Management Co. grew its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,664,578 shares of the biotechnology company’s stock after purchasing an additional 169,971 shares during the period. Congress Asset Management Co. owned 3.29% of Vericel worth $59,941,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VCEL. Diversified Trust Co. lifted its holdings in Vericel by 108.5% in the fourth quarter. Diversified Trust Co. now owns 23,061 shares of the biotechnology company’s stock worth $830,000 after acquiring an additional 12,000 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Vericel by 72.5% during the 4th quarter. GAMMA Investing LLC now owns 3,903 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 1,640 shares during the period. JPMorgan Chase & Co. raised its position in shares of Vericel by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 268,983 shares of the biotechnology company’s stock worth $8,465,000 after purchasing an additional 2,530 shares during the period. Tudor Investment Corp ET AL acquired a new stake in Vericel in the third quarter worth $625,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Vericel in the 3rd quarter worth about $519,000.

Vericel Trading Up 3.3%

Shares of NASDAQ:VCEL opened at $32.45 on Tuesday. The company has a 50 day moving average of $35.69 and a 200-day moving average of $35.84. The firm has a market cap of $1.65 billion, a P/E ratio of 104.68 and a beta of 1.22. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $48.74.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, meeting analysts’ consensus estimates of $0.45. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The business had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. During the same quarter last year, the business earned $0.38 earnings per share. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. Equities research analysts forecast that Vericel Corporation will post 0.14 EPS for the current year.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of recent analyst reports. Truist Financial cut their price target on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Wall Street Zen cut Vericel from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. HC Wainwright lifted their target price on Vericel from $60.00 to $64.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Finally, Leerink Partners reissued an “outperform” rating and issued a $46.00 price target on shares of Vericel in a research note on Tuesday, March 10th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $56.00.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.